BrainsWay announces strategic collaboration with Mindful Health Solutions
The neurostimulation device maker said it will work with the behavioral health provider to expand access to its Deep TMS therapies, as filed with the SEC on November 2, 2026.
BrainsWay Ltd. announced a strategic collaboration with Mindful Health Solutions on November 2, 2026, according to a press release filed with the SEC. BrainsWay described itself as a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, and characterized MHS as an established provider of comprehensive behavioral health and interventional psychiatry services.1
The release noted that Mindful Health Solutions' managed services organization was acquired by Radial Health, Inc. in August 2026.1 Following that acquisition, the combined entity operates under the name Radial and runs 27 clinic locations across California, Missouri, New York, South Carolina, Tennessee, Texas and Washington, which the companies describe as the largest network of brain medicine clinics in the US.1
Under the new collaboration, the two companies plan to broaden availability of BrainsWay's Deep TMS technology and its newly cleared accelerated "SWIFT" protocol, and said they would also look into incorporating Neurolief's ProlivRx at-home neuromodulation device into patient treatment plans, per the release. The companies also said they intend to pursue physician education and clinical awareness efforts, including key opinion leader programs, educational events, outreach to healthcare professionals, and research into complementary treatment approaches.1
BrainsWay CEO Hadar Levy commented on the partnership, saying the company was "elated to collaborate with Mindful Health Solutions," according to the release.
The announcement followed other recent moves by BrainsWay, including a follow-on equity investment of $0.8 million in the management services organization behind the Texas-based "Heading Health" clinic network.1 BrainsWay describes itself as the first and only TMS company with three FDA-cleared indications backed by pivotal clinical studies, covering major depressive disorder, obsessive-compulsive disorder, and smoking addiction.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.